Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00299949 · ClinicalTrials.gov registry record

Thrombin Generation and Thromboelastography in Non-overt DIC

A clinical trial, sponsored by The University of Texas Health Science Center, Houston.

Terminated
Registry status
2
Enrollment target

NCT00299949 is a clinical trial that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00299949 was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.

TERMINATED
Registry status
2 participants
Enrollment target

Study Summary

Sepsis is the 13th most common cause of death in the United States, causing approximately 210,000 deaths per year. Once DIC has developed, irreversible organ injury has already occurred and the mortality rate is 70%. Inhibition of systemic coagulation with activated protein C concentrate has been the only therapy for sepsis introduced in the past several decades which has improved outcomes. Elucidation of the coagulopathic mechanisms early in the development of DIC may give rise to targeted therapies and strategies for early intervention. We hypothesize that an increase in endogenous thrombin potential precedes the development of overt DIC by a clinically significant time period. Our primary objective is to determine if endogenous thrombin potential (ETP) measured at first diagnosis of sepsis prior to the onset of DIC and organ failure is predictive of overt DIC and/or poor outcome. We will compare ETP to standard coagulation assays and the clinical assessment of DIC using the ISTH criteria for overt DIC. A secondary objective of this study is to determine if host coagulation variables predispose to the development of DIC and poor clinical outcome during sepsis.

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2006-10
Est. Completion 2008-12

What the Registry Record Tells You About NCT00299949

The ClinicalTrials.gov registry entry for NCT00299949 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00299949 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00299949 about?

NCT00299949 is a clinical study titled "Thrombin Generation and Thromboelastography in Non-overt DIC". Sepsis is the 13th most common cause of death in the United States, causing approximately 210,000 deaths per year. Once DIC has developed, irreversible organ injury has already occurred and the mortality rate is 70%. Inhibition of systemic coagulation with activated protein C concentrate has been th...

What is the current status of trial NCT00299949?

This trial is currently terminated. The enrollment target is 2 participants. The study started on 2006-10. Estimated completion is 2008-12.

Who is sponsoring clinical trial NCT00299949?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.